US 2017/0333395 A1Published application

Spiro-lactam nmda receptor modulators and uses thereof

AssigneeApytinyx Inc.

InventorM. Amin Khan

Life of this patent

Estimating the term…

Abstract

Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Claims6

Dependent claims

A compound having the formula:

or a stereoisomer and/or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application: 15/636,888Filed 29 Jun 2017
Priority: 19 May 2016
Published: 23 Nov 2017
Term ends: Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61K 31/40
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having five-membered rings with one nitrogen as the only ring hetero atom,…
A61K 31/045
Medicinal preparations containing organic active ingredients: hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
A61K 31/095
Medicinal preparations containing organic active ingredients: sulfur, selenium, or tellurium compounds, e.g. thiols
A61K 31/16
Medicinal preparations containing organic active ingredients: amides, e.g. hydroxamic acids

Family

Application62/338,772Us provisional application · filed 19 May 2016
Application15/636,888Continuation
US 9,925,169 B2Related patent
US 2017/0333395 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results